Christopher Fortner, MD, PhD

Christopher Fortner, MD, PhD
Appointed 04/09/12
Upstate University Hospital - Downtown Campus
750 East Adams Street
Syracuse, NY 13210

315 464-6323

Current Appointments

Hospital Campus

  • Downtown

Clinical Section Affiliations

  • Pediatrics: Pediatric Pulmonary Medicine

Clinic/Unit

Education & Fellowships

  • Fellowship: Duke University Medical Center, 2008, Pediatric Pulmonology
  • Residency: Duke University Medical Center, 2006, Pediatrics
  • MD/PhD: University of Cincinnati College of Medicine, 2002, Physiology

Previous Appointments

  • Duke University Medical Center, 2009–2012

Clinical Interests

  • Cystic fibrosis, asthma, chronic cough

Education Interests

  • Cystic fibrosis, airway physiology

Research Interests

  • Cystic Fibrosis clinical trials

Clinical Trials

  • A Phase 2a, Randomized, Double-blind, Placebo-controlled, Incomplete Block, Crossover Study to Evaluate the Safety and Efficacy of VX-371 in Subjects Aged 12 Years or Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation, and Being Treated With Orkambi.
    Read more
  • A PHASE 3 EFFICACY AND SAFETY STUDY OF ATALUREN (PTC124®) IN PATIENTS WITH NONSENSE MUTATION CYSTIC FIBROSIS (PTC124-GD-021-CF)
    Read more
  • A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
    Read more
  • A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation (VX14-661-106)
    Read more
  • A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment with Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Years and Older With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
    Read more
  • OPTIMIZing Treatment for Early Pseudomonas aeruginosa infection in Cystic Fibrosis. The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial. (OPTIMIZE-IP-12)
    Read more
  • Participation in the Cystic Fibrosis Patient Registry
    Read more

Specialties & Certification

  • Pediatrics
  • Pediatric Pulmonary

Diseases & Conditions Treated

  • Asthma
  • Cystic Fibrosis (CF)

Treats

  • Children

Treatments/Services

  • Fiberoptic Bronchoscopy

Current Hospital Privileges

  • Upstate University Hospital
  • Crouse Hospital

Publications

Link to PubMed External Icon (Opens new window. Close the PubMed window to return to this page.)

Clinical Profile Shortcut: http://www.upstate.edu/findadoc/fortnerc
Faculty Profile Shortcut: http://www.upstate.edu/faculty/fortnerc